{"prompt": "['Novartis', 'Confidential', 'Page 29', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'QAW039 150 mg once daily (one tablet of blinded QAW039 at 150 mg dosage strength to', 'be given together with one tablet blinded placebo to QAW039 450 mg).', 'QAW039 450 mg once daily (one tablet of blinded QAW039 at 450 mg dosage strength to', 'be given together with one tablet blinded placebo to QAW039 150 mg).', 'Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one', 'tablet blinded placebo to QAW039 450 mg).', 'Patients will be instructed to take their investigational treatment (QAW039 or placebo) once', 'daily in the morning without regard to time of food intake.', '6.1.4', 'Treatment duration', 'The planned duration of the study treatment period is 16 weeks from the point of randomization.', 'Subjects will take their assigned study treatments along with the NP SoC which will be supplied', 'to patients at the start of the Run-in period. The patients will administer the SoC only, during', 'the Run-in period and then administer both the SoC and the study treatment, during the 16-week', 'Treatment period.', '6.2', 'Other treatment(s)', 'All', 'patients will be provided with short-acting \u00df2-agonists (SABAs)', '(salbutamol/albuterol/other SABA) which they will be instructed to use throughout the study as', \"rescue medication on an 'as needed basis.\", '6.2.1', 'Concomitant therapy', 'All medications, procedures and significant non-drug therapies (including physical therapy and', 'blood transfusions) administered after the subject was enrolled into the study must be recorded', 'on the appropriate Case Report Forms (CRFs). The medications in Table 6-1 are only permitted', 'under the circumstances given and this table is not considered all-inclusive.', 'Each concomitant drug must be individually assessed for adherence to the indication and against', 'all exclusion criteria/prohibited medication. If in doubt the Investigator should contact the', 'Novartis/sponsor medical monitor before randomizing a subject or allowing a new medication', 'to be started. If the subject is already enrolled, contact Novartis/sponsor to determine if the', 'subject should continue participation in the study.', 'Table 6-1', 'Medications allowed under certain conditions', 'Class of medication', 'Conditions', 'Short-acting \u00df2-agonist (SABA)', 'Rescue medication to be taken as needed', 'SCS for treatment of symptoms of asthma or NP', 'One treatment of up to 5 consecutive days allowed during', 'the study. SCS should not be administered within the 2', 'weeks prior to nasal endoscopy', 'Maintenance Immunotherapy for allergies', 'Stable dose for at least 3 months prior to Screening and', 'the dose remains stable throughout the study', 'Inactivated influenza vaccine, pneumococcal', 'Not administered with 48 hour prior to a study visit', 'vaccine or any other inactivated vaccine', 'Topical corticosteroids for treatment of eczema', 'Recommended doses and dosage regimens']['Novartis', 'Confidential', 'Page 30', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Class of medication', 'Conditions', 'Antihistamines (e.g. loratadine, cetirizine)', 'Stable for at least 1 month prior to Screening visit and', 'dose remains stable throughout the study', 'Nasal anticholinergic', 'Treatment regimen has been stable for at least 1 month', 'Nasal or ophthalmological preparations of', 'prior to Screening visit. In the case of as needed use,', 'nedocromil', 'providing an established pattern of use, has been', 'documented', 'Nasal or ophthalmological preparations of', 'antihistamines', '6.2.2', 'Prohibited medication', 'Use of the treatments displayed in the below table is NOT allowed after screening. Each', 'concomitant drug must be individually assessed against all exclusion criteria and the tables', 'below to see if it is allowed. If in doubt, the Investigator should contact the Novartis medical', 'monitor or designee before randomizing a patient or allowing a new medication to be started.', 'This table is not considered all-inclusive. Medications should be assessed for adherence to the', 'indication and other inclusion/exclusion criteria. These medications are also prohibited', 'if', 'administered for other indications.', 'Table 6-2', 'Prohibited Medication', 'Medication', 'Prohibition period (Minimum cessation prior to Run-in)', 'Other investigational drugs', '30 days or 5 half-lives, whichever is longer', 'Oral and Nasal Decongestants (more than 3 weeks', '30 days', 'total use)', 'Live attenuated vaccine', '30 days', 'Simvastatin > 20 mg, atorvastatin > 40 mg,', '7 days', 'pravastatin > 40 mg, or pitavastatin > 2 mg total', 'daily dose', 'Other DP2 antagonists (e.g., ramatroban)', '7 days or 5 half-lives whichever is longer', 'Short-acting anticholinergics', '8 hours', 'Fixed combinations of short-acting \u00df2 agonists and', '8 hours', 'short-acting anticholinergics', 'Systemic mast cell stabilizers (e.g.,cromoglycate,', '7 days', 'nedocromil, ketotifen)', 'Monoclonal antibodies, investigational or approved,', '6 months', 'for the treatment of asthma (e.g., omalizumab)', 'Nasal corticosteroids in the form of drops, sprays', '8 weeks', 'that are administered via devices (e.g. OptiNose', 'device or stents) or lavage', 'Tetracyclic or macrolide antibiotics', '8 weeks', 'Rifampin, probenecid, ritonavir and valproic acid', '7 days', '(i.e. medications blocking several pathways', 'important for the elimination of QAW039 (broad', 'range UGT inhibition and/or inhibition of OAT3,', 'OATP1B3, MXR and P-gp)).', 'Methotrexate, gold salts, cyclosporine,', '6 months', 'troleandomycin, azathioprine, other immuno-', 'modulator drugs or immuno-modulatory monoclonal', 'antibodies', 'Systemic (oral, intravenous, intramuscular)', '3 months', 'corticosteroids for non-asthma conditions']\n\n###\n\n", "completion": "END"}